Matthew Barcus
Stock Analyst at Chardan Capital
(2.27)
# 2,422
Out of 4,829 analysts
21
Total ratings
20.83%
Success rate
18.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.25 | +703.21% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $13.15 | +105.32% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.73 | +857.59% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $14.55 | +119.93% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.25 | +9,677.78% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.66 | +238.35% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $7.94 | +0.76% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.25
Upside: +703.21%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $13.15
Upside: +105.32%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.73
Upside: +857.59%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $14.55
Upside: +119.93%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.25
Upside: +9,677.78%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.66
Upside: +238.35%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $7.94
Upside: +0.76%